Benefiting from the natural tumor-tropism of EcN and the enhanced permeability and retention (EPR) effect, scFv was packaged into OMVs and selectively delivered to hypoxic tumor regions, where it bound TREM2-expressing macrophages to alleviate immunosuppression (Wang et al., 2025). Here, TREM2 is linked to neoplasm.